The pharmacokinetic, pharmacodynamic and pharmacogenomic outcomes of reduced dosage of efavirenz: the Encore1 study [ 2013 - 2015 ]

Also known as: PK/PGX outcomes in Encore1

Research Grant

[Cite as]

Researchers: Dr Rebekah Puls (Principal investigator) ,  Dr Alan Winston Dr Amanda Clarke Dr Catherine Orrell Dr Dianne Carey
View all 9 related researchers

Brief description Our primary aim is to assess blood concentrations of a drug called efavirenz, an important drug used in the treatment of HIV infection and associate these with variability of genes that control metabolism of the drug. A better understanding of gene variability and how it relates to safety and efficacy outcomes at a reduced, compared to a standard dose of efavirenz could support improved treatment of HIV disease.

Funding Amount $AUD 1,234,943.66

Funding Scheme Project Grants

Notes Standard Project Grant

Click to explore relationships graph
Viewed: [[ro.stat.viewed]]